drugset / Trial / NCT01231620

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620

Phase 3 Completed 626 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.

Timeline

Start
2011-01-15
Primary completion
2015-03-18
Completion
2015-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Oseltamivir Small molecule 75 mg Oral
Subject Zanamivir Small molecule 300 mg Intravenous
Subject Zanamivir Small molecule 600 mg Intravenous

Indications